NASDAQ:TTOO T2 Biosystems (TTOO) Stock Price, News & Analysis → They said crypto was dead. It went up 100X. (From InvestorPlace) (Ad) Free TTOO Stock Alerts $3.93 -0.25 (-5.98%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$3.60▼$4.3250-Day Range$3.82▼$6.4952-Week Range$3.36▼$70.00Volume232,006 shsAverage Volume264,150 shsMarket Capitalization$15.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get T2 Biosystems alerts: Email Address Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. About T2 Biosystems Stock (NASDAQ:TTOO)T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Read More TTOO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTOO Stock News HeadlinesMarch 18, 2024 | globenewswire.comT2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance PanelMarch 14, 2024 | americanbankingnews.comAethlon Medical (NASDAQ:AEMD) and T2 Biosystems (NASDAQ:TTOO) Head-To-Head ReviewMarch 18, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.March 12, 2024 | investorplace.comTTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq ComplianceMarch 12, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementMarch 12, 2024 | globenewswire.comT2 Biosystems Receives Extension to Comply with Nasdaq Listing RequirementFebruary 16, 2024 | money.usnews.comT2 Biosystems IncFebruary 16, 2024 | finance.yahoo.comT2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call TranscriptMarch 18, 2024 | Paradigm Press (Ad)8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)THIS cryptocurrency has gained 40% in 6 months. A crypto millionaire who has researched the space for a decade says it will go up 8,788% in 5 years. The name of this cryptocurrency is revealed right here: February 16, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaFebruary 16, 2024 | finance.yahoo.comQ4 2023 T2 Biosystems Inc Earnings CallFebruary 15, 2024 | finance.yahoo.comT2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaFebruary 15, 2024 | finance.yahoo.comT2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into EquityFebruary 15, 2024 | finance.yahoo.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | globenewswire.comT2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | globenewswire.comT2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into EquityFebruary 15, 2024 | globenewswire.comT2 Biosystems Announces Commercial Expansion Through Distributors in Europe and AsiaFebruary 14, 2024 | benzinga.comEarnings Preview For T2 BiosystemsFebruary 12, 2024 | marketwatch.comT2 Biosystems Gets 510(k) Clearance For Expanded T2Bacteria PanelFebruary 12, 2024 | finanznachrichten.deT2 Biosystems, Inc.: T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria PanelFebruary 12, 2024 | msn.comT2 Biosystems spikes as FDA clearance for T2Bacteria Panel expandsFebruary 12, 2024 | markets.businessinsider.comT2 Biosystems Receives 510(K) Clearance for Its Bacteria PanelFebruary 12, 2024 | msn.comWhy T2 Biosystems Stock Is Up TodayFebruary 12, 2024 | markets.businessinsider.comT2 Biosystems Announces FDA 510(k) Clearance For Expanded T2Bacteria PanelFebruary 12, 2024 | finance.yahoo.comT2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria PanelFebruary 7, 2024 | finance.yahoo.comT2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024February 7, 2024 | finance.yahoo.comU.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics PrizeSee More Headlines Receive TTOO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today3/18/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:TTOO CUSIPN/A CIK1492674 Webwww.t2biosystems.com Phone(781) 761-4646Fax781-357-3080Employees158Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,000,000.00 Net Margins-453.18% Pretax Margin-453.21% Return on EquityN/A Return on Assets-129.56% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.52 Sales & Book Value Annual Sales$22.31 million Price / Sales0.71 Cash FlowN/A Price / Cash FlowN/A Book Value($513.90) per share Price / Book-0.01Miscellaneous Outstanding Shares4,050,000Free Float3,333,000Market Cap$15.92 million OptionableOptionable Beta0.14 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. John J. Sperzel III (Age 61)B.Sc., President, CEO & Chairman Comp: $865.5kMr. John M. Sprague CPA (Age 66)Chief Financial Officer Comp: $482.33kMr. Michael Terrence Gibbs Esq. (Age 53)Senior VP, General Counsel & Company Secretary Comp: $487.33kMs. Kelley J. Morgan (Age 48)Chief People Officer Mr. Brett A. Giffin (Age 65)Chief Commercial Officer Dr. Roger Smith Ph.D. (Age 59)Senior Vice President of Science Research & Development More ExecutivesKey CompetitorsMicrobot MedicalNASDAQ:MBOTNEXGELNASDAQ:NXGLPetVivoNASDAQ:PETVSTRATA Skin SciencesNASDAQ:SSKNBiotricityNASDAQ:BTCYView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 5,836,468 shares on 3/11/2024Ownership: 1.370%Virtu Financial LLCBought 10,078 shares on 2/26/2024Ownership: 0.302%GSA Capital Partners LLPSold 2,559,030 shares on 2/16/2024Ownership: 0.616%Vanguard Group Inc.Sold 5,836,468 shares on 2/15/2024Ownership: 1.368%Citadel Advisors LLCSold 1,800 shares on 2/15/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions TTOO Stock Analysis - Frequently Asked Questions How have TTOO shares performed in 2024? T2 Biosystems' stock was trading at $6.28 at the beginning of 2024. Since then, TTOO stock has decreased by 37.4% and is now trading at $3.93. View the best growth stocks for 2024 here. Are investors shorting T2 Biosystems? T2 Biosystems saw a decline in short interest in the month of February. As of February 29th, there was short interest totaling 316,400 shares, a decline of 25.4% from the February 14th total of 424,000 shares. Based on an average trading volume of 334,900 shares, the short-interest ratio is presently 0.9 days. Approximately 9.9% of the shares of the company are sold short. View T2 Biosystems' Short Interest. When is T2 Biosystems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our TTOO earnings forecast. How were T2 Biosystems' earnings last quarter? T2 Biosystems, Inc. (NASDAQ:TTOO) issued its quarterly earnings results on Thursday, November, 4th. The medical equipment provider reported ($400.00) earnings per share for the quarter, hitting analysts' consensus estimates of ($400.00). The medical equipment provider earned $7.43 million during the quarter. During the same quarter in the previous year, the firm earned ($400.00) earnings per share. When did T2 Biosystems' stock split? T2 Biosystems shares reverse split on Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What guidance has T2 Biosystems issued on next quarter's earnings? T2 Biosystems issued an update on its fourth quarter 2023 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.7 million-$1.7 million, compared to the consensus revenue estimate of $2.4 million. What is John McDonough's approval rating as T2 Biosystems' CEO? 36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of T2 Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT). Who are T2 Biosystems' major shareholders? T2 Biosystems' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.37%), Vanguard Group Inc. (1.37%), GSA Capital Partners LLP (0.62%), Virtu Financial LLC (0.30%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adrian M Jones, Alec Barclay, Brett A Giffin, Goldman Sachs & Co Llc, Group LP Cr, John J Sperzel III, John M Sprague, John Mcdonough and Michael Terrence Gibbs. View institutional ownership trends. How do I buy shares of T2 Biosystems? Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TTOO) was last updated on 3/18/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial MetalsLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingBill Gates Bets on $15 Trillion BonanzaWeiss RatingsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding T2 Biosystems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.